Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.27+0.38 (+9.77%)
Close on Nov 13, 2026Market cap $774.48MP/E –Yield –
Prime Medicine r&d expenses
Research and development expenses are spending on new products and technology.
Prime Medicine's R&D Expenses for the twelve months ending Sep 30, 2026 was $136.33M, down 14.8% year over year. For fiscal 2025 it was $160.64M, up 3.4% from the year before. The highest annual figure on record is $160.64M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.64M | +3.4% |
| FY2024 | Dec 31, 2024 | $155.29M | +5.0% |
| FY2023 | Dec 31, 2023 | $147.91M | +70.5% |
| FY2022 | Dec 31, 2022 | $86.73M | +22.9% |
| FY2021 | Dec 31, 2021 | $70.55M | +2267.4% |
| FY2020 | Dec 31, 2020 | $2.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.12M | -22.4% |
| Q2 FY2026 | Jun 30, 2026 | $33.40M | -19.3% |
| Q1 FY2026 | Mar 31, 2026 | $34.11M | -15.9% |
| Q4 FY2025 | Dec 31, 2025 | $34.71M | +1.8% |
| Q3 FY2025 | Sep 30, 2025 | $43.99M | +9.0% |
| Q2 FY2025 | Jun 30, 2025 | $41.38M | -3.9% |
| Q1 FY2025 | Mar 31, 2025 | $40.56M | +7.4% |
| Q4 FY2024 | Dec 31, 2024 | $34.10M | -17.7% |
| Q3 FY2024 | Sep 30, 2024 | $40.34M | -1.5% |
| Q2 FY2024 | Jun 30, 2024 | $43.07M | +24.5% |
| Q1 FY2024 | Mar 31, 2024 | $37.77M | +22.3% |
| Q4 FY2023 | Dec 31, 2023 | $41.46M | +42.7% |
| Q3 FY2023 | Sep 30, 2023 | $40.97M | +63.6% |
| Q2 FY2023 | Jun 30, 2023 | $34.60M | +153.0% |
| Q1 FY2023 | Mar 31, 2023 | $30.88M | -41.6% |
| Q4 FY2022 | Dec 31, 2022 | $29.06M | +292.7% |
| Q3 FY2022 | Sep 30, 2022 | $25.05M | – |
| Q1 FY2022 | Mar 31, 2022 | $13.68M | – |
| Q4 FY2021 | Dec 31, 2021 | $52.89M | – |
| Q3 FY2021 | Sep 30, 2021 | $7.40M | – |
See a number that looks wrong?